[Effectiveness and safety of bicyclol combined with thymosin in treatment of chronic viral hepatitis B].
OBJECTIVE
To analyze the efficacy and safety of bicyclol combined with thymosin in treatment of chronic viral hepatitis B (CHB).


METHODS
A total of 135 patients with CHB were randomized into experimental group and control group. The patients in the experimental group received bicyclol orally 75 mg daily and thymosin 20 mg intramuscular injection once every 2 days for 24 weeks and those in control group received bicyclol orally 75 mg daily alone for 24 weeks. The levels of serum aminotransferase (ALT/AST), HBV-DNA, HBeAg /antiHBe were observed.


RESULTS
Compared with pre-treatment levels, the serum aminotransferase levels decreased significantly in both groups, but there were no statistically significant differences between them. HBeAg negative conversion rate was significantly higher in the experimental group than in the control group (35.3 percent vs.19.4 percent, P less than 0.05). HBV DNA negative conversion rate was significantly higher in the experimental group than in the control group (36.7 percent vs. 20.9 percent, P less than 0.05). No obvious adverse events which were probably related to the drugs were observed in this study.


CONCLUSIONS
The combination of bicyclol with thymosin had better effect in treatment of chronic hepatitis B ias compared with bicyvlol alone.
Hou
Shi-rong
SR
Nanjing Gulou Hospital, Nanjing 210008 China.
Xie
Bi-hong
BH
Gu
Xiao-jun
XJ
Yan
Xiao-min
XM
Qiu
Jie
J
D000293:Adolescent; D000328:Adult; D001713:Biphenyl Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D013947:Thymosin / Q000008:administration & dosage* / Q000009:adverse effects
D001713:Biphenyl Compounds; D013947:Thymosin; C477843:bicyclol